ATE211384T1 - Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera - Google Patents
Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulceraInfo
- Publication number
- ATE211384T1 ATE211384T1 AT92101308T AT92101308T ATE211384T1 AT E211384 T1 ATE211384 T1 AT E211384T1 AT 92101308 T AT92101308 T AT 92101308T AT 92101308 T AT92101308 T AT 92101308T AT E211384 T1 ATE211384 T1 AT E211384T1
- Authority
- AT
- Austria
- Prior art keywords
- ulceras
- prevent
- adenosine antagonists
- treat pancreatitis
- pancreatitis
- Prior art date
Links
- 206010033645 Pancreatitis Diseases 0.000 title abstract 2
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 title abstract 2
- 208000025865 Ulcer Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 231100000397 ulcer Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64832091A | 1991-01-29 | 1991-01-29 | |
| US07/715,460 US5155114A (en) | 1989-01-23 | 1991-06-14 | Method of treatment using pyrazolopyridine compound |
| PH42760A PH30486A (en) | 1990-07-18 | 1991-07-09 | Pyrazolopyridine compound and processes for preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE211384T1 true ATE211384T1 (de) | 2002-01-15 |
Family
ID=27354002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT92101308T ATE211384T1 (de) | 1991-01-29 | 1992-01-28 | Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0497258B1 (de) |
| JP (1) | JPH0558913A (de) |
| AT (1) | ATE211384T1 (de) |
| CA (1) | CA2060138A1 (de) |
| DE (1) | DE69232323T2 (de) |
| MX (1) | MX9200361A (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5565566A (en) * | 1987-04-24 | 1996-10-15 | Discovery Therapeutics, Inc. | N6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists |
| US5395836A (en) * | 1993-04-07 | 1995-03-07 | Kyowa Hakko Kogyo Co., Ltd. | 8-tricycloalkyl xanthine derivatives |
| US5541213A (en) * | 1993-06-24 | 1996-07-30 | Eisai Co., Ltd. | Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility |
| US5646156A (en) * | 1994-04-25 | 1997-07-08 | Merck & Co., Inc. | Inhibition of eosinophil activation through A3 adenosine receptor antagonism |
| CA2167314A1 (en) * | 1994-05-17 | 1995-11-23 | Junichi Shimada | Process for producing xanthine derivative |
| US5670501A (en) * | 1994-09-01 | 1997-09-23 | Discovery Therapeutics, Inc. | N-substituted 9-alkyladenines |
| CA2267103C (en) * | 1996-10-04 | 2006-05-30 | Kyorin Pharmaceutical Co., Ltd. | Pyrazolopyridylpyridazinone derivatives and process for the preparation thereof |
| WO1998041237A1 (en) * | 1997-03-18 | 1998-09-24 | Fujisawa Pharmaceutical Co., Ltd. | Preventives and remedies for hyperphosphatemia |
| EP0870502A3 (de) * | 1997-04-10 | 2001-04-04 | Kyowa Hakko Kogyo Co., Ltd. | Verwendung von Adenosinaufnahmeinhibitoren zur Herstellung eines Arzneimittels zur Behandlung von Pankreatitis |
| WO1999067239A1 (en) * | 1998-06-22 | 1999-12-29 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazolopyridine compounds and medicinal uses thereof |
| US7732484B2 (en) | 2000-08-01 | 2010-06-08 | University Of Virginia Patent Foundation | Use of selective adenosine A1 receptor allosteric enhancers to manipulate angiogenesis |
| PE20020506A1 (es) | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
| WO2002048148A2 (en) | 2000-12-15 | 2002-06-20 | Glaxo Group Limited | Pyrazolopyridine derivatives |
| ATE301653T1 (de) | 2000-12-15 | 2005-08-15 | Glaxo Group Ltd | Pyrazolopyridine |
| DE60201074T2 (de) | 2001-03-08 | 2005-09-15 | Smithkline Beecham Corp. | Pyrazolopyridinderivate |
| EP1372643A1 (de) | 2001-03-30 | 2004-01-02 | Smithkline Beecham Corporation | Pyrazolopyridine, verfahren zu ihrer herstellung und verwendung als therapeutika |
| US7141569B2 (en) | 2001-04-10 | 2006-11-28 | Smithkline Beecham Corporation | Antiviral pyrazolopyridine compounds |
| ES2242028T3 (es) | 2001-04-27 | 2005-11-01 | Smithkline Beecham Corporation | Derivados de pirazolo(1,5-a)piridina. |
| PL214231B1 (pl) | 2001-04-27 | 2013-07-31 | Eisai R & D Man Co | Pochodne pirazolo [1,5-a] pirydyny, kompozycje je zawierajace oraz zastosowanie |
| HUP0400266A2 (hu) | 2001-06-21 | 2004-08-30 | Smithkline Beecham Corp. | Imidazo[1,2-a]piridin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk herpeszvírus-fertőzések megelőzésére vagy kezelésére |
| WO2003031446A1 (en) | 2001-10-05 | 2003-04-17 | Smithkline Beecham Corporation | Imidazo-pyridine derivatives for use in the treatment of herpes viral infection |
| AU2002357740A1 (en) | 2001-12-11 | 2003-06-23 | Smithkline Beecham Corporation | Pyrazolo-pyridine derivatives as antiherpes agents |
| JP2006504728A (ja) | 2002-10-03 | 2006-02-09 | スミスクライン ビーチャム コーポレーション | ピラソロピリジン誘導体系治療用化合物 |
| US7247639B2 (en) * | 2003-06-06 | 2007-07-24 | Endacea, Inc. | A1 adenosine receptor antagonists |
| SI2266990T1 (sl) | 2008-04-15 | 2013-01-31 | Eisai R&D Management Co. Ltd. | Spojina 3-fenilpirazolo(5,1-b)tiazola |
| EP2320737B1 (de) | 2008-08-05 | 2013-07-17 | Merck Sharp & Dohme Corp. | Pyrazolo-[1,5-a]-pyridine als mark-hemmer |
| AR078521A1 (es) | 2009-10-08 | 2011-11-16 | Eisai R&D Man Co Ltd | Compuesto pirazolotiazol |
| EP2855489B1 (de) | 2012-04-26 | 2017-01-04 | Bristol-Myers Squibb Company | Imidazothiadiazol- und imidazopyridazinderivate als proteaseaktivierte rezeptor 4 (par4)-inhibitoren zur behandlung von thrombozytenaggregation |
| EA201491967A1 (ru) | 2012-04-26 | 2015-03-31 | Бристол-Майерс Сквибб Компани | Производные имидазотиадиазола в качестве ингибиторов активируемых протеазой рецепторов 4 (par4) для лечения агрегации тромбоцитов |
| SMT201700457T1 (it) | 2012-04-26 | 2017-11-15 | Bristol Myers Squibb Co | DERlVATI IMIDAZOTIADIAZOLICI E IMIDAZOPIRAZINICI COME INIBITORI DEL RECETTORE ATTIVATO DA PROTEASI 4 (PAR4) PER IL TRATTAMENTO DELL'AGGREGAZIONE PIASTRINICA |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES482789A0 (es) * | 1978-08-25 | 1980-12-01 | Thomae Gmbh Dr K | Procedimiento para la preparacion de nuevos bencimidazoles sustituidos en posicion 5 o 6 con un anillo de piridazinona |
| DE3536030A1 (de) * | 1985-10-09 | 1987-04-09 | Thomae Gmbh Dr K | Verwendung von benzimidazolen zur behandlung der migraene |
| US4925849A (en) * | 1987-06-15 | 1990-05-15 | Fujisawa Pharmaceutical Company, Ltd. | Pharmaceutically useful pyrazolopyridines |
| AU5436790A (en) * | 1989-04-19 | 1990-11-16 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Sulfer-containing xanthine derivatives as adenosin antagonists |
| GB9015764D0 (en) * | 1990-07-18 | 1990-09-05 | Fujisawa Pharmaceutical Co | Pyrazolopyridine compound and processes for preparation thereof |
-
1992
- 1992-01-28 CA CA002060138A patent/CA2060138A1/en not_active Abandoned
- 1992-01-28 AT AT92101308T patent/ATE211384T1/de active
- 1992-01-28 EP EP92101308A patent/EP0497258B1/de not_active Expired - Lifetime
- 1992-01-28 DE DE69232323T patent/DE69232323T2/de not_active Expired - Fee Related
- 1992-01-29 MX MX9200361A patent/MX9200361A/es not_active IP Right Cessation
- 1992-01-29 JP JP4013506A patent/JPH0558913A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP0497258B1 (de) | 2002-01-02 |
| EP0497258A2 (de) | 1992-08-05 |
| CA2060138A1 (en) | 1992-07-30 |
| MX9200361A (es) | 1992-07-01 |
| JPH0558913A (ja) | 1993-03-09 |
| DE69232323T2 (de) | 2002-08-08 |
| DE69232323D1 (de) | 2002-02-07 |
| EP0497258A3 (en) | 1993-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69232323D1 (de) | Verwendung von Adenosinantagonisten zur Vorbeugung und Behandlung von Pankreatitis und Ulcera | |
| ATE175412T1 (de) | Hiv-protease-inhibitoren | |
| UA26213C2 (uk) | Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові | |
| ATE203019T1 (de) | Neue (r)-5-carbamoyl-8-fluor-3-n,n- disubstituierte-amino-3,4-dihydro-2h-1- benzopyrane | |
| TW376319B (en) | Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine | |
| DE69727158D1 (de) | Pharmazeutische zusammensetzungen enthaltend eine mischung von selbstvernetzter und nichtselbstvernetzter hyaluronsäure zur behandlung von arthropathien | |
| DE69034148D1 (de) | Kombinationstherapie zur Prophylaxe und/oder Behandlung von gutartiger prostatischer Hyperplasie | |
| ATE142877T1 (de) | Melatoninderivate zur behandlung von schlafstörungen und zur pre-anästhesie | |
| ATE209490T1 (de) | Substanz p antagonisten zur behandlung von erbrechen | |
| ATE201597T1 (de) | Verabreichung von riluzol zur behandlung von neuro-aids | |
| NO307645B1 (no) | Anvendelse av probenecid i kombinasjon med en eksitatorisk aminosyre-antagonist for fremstilling av et farmasøytisk preparat | |
| ATE165514T1 (de) | Verwendung von inosittriphosphat zur zubereitung von medikamenten | |
| ES2160643T3 (es) | Composiciones que contienen g-csf y proteina de union al tnf. | |
| ATE253373T1 (de) | Verwendung von physiologisch verträglichen vanadiumverbindungen, salzen und komplexen | |
| ES2093357T3 (es) | Metodo de tratamiento de la alopecia. | |
| IT1240683B (it) | Composizione farmaceutica contenente egf | |
| FI101849B1 (fi) | Antimikrobiset koostumukset ja niiden käyttö silmälääkkeiden säilömiseksi ja piilolinssien hoitamiseksi | |
| ATE204476T1 (de) | Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazi e zur herstrllung eines medikaments zur behandlung von bestimmten schmerzen und ödem | |
| ATE193206T1 (de) | Zusammensetzung zur behandlung oder vorbeugung von herpes | |
| NO893256D0 (no) | Fremgangsmaate for fremstilling av furyltiazolderivater. | |
| TR199900141T2 (xx) | Bunama tedavisi ve/veya profilaksisi i�in form�lasyon. | |
| FI914410A0 (fi) | Kalciumupptagande inhibitorer. | |
| TR200102009T2 (tr) | Serebral işlemi profilaksı ve tedavisi için formül I'e göre bileşiklerin kullanımı | |
| DE59410340D1 (de) | Verwendung von Bradykinin-Antagonisten zur Behandlung von Viruserkrankungen | |
| ES2190499T3 (es) | Uso de antagonistas de bradiquinina para la preparacion de medicamentos para el tratamiento y la prevencion de la enfermedad de alzheimer. |